Who are Clindamycin+Dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antibiotics + Corticosteroids, Tobramycin + Dexamethasone, moxifloxacin / dexamethasone, Moxifloxacin / Dexamethasone Ophthalmic Solution, Levofloxacin + dexamethasone followed by dexamethasone, Ciprofloxacin HCl and Hydrocortisone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clindamycin-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Clindamycin+Dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clindamycin+Dexamethasone (Clindamycin+Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic + Corticosteroid combination. Area: Infectious Disease / Immunology.

phase 3 Antibiotic + Corticosteroid combination Bacterial 50S ribosome (clindamycin); Glucocorticoid receptor (dexamethasone) Infectious Disease / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Clindamycin+Dexamethasone (Clindamycin+Dexamethasone) — Shahid Beheshti University of Medical Sciences. Clindamycin inhibits bacterial protein synthesis while dexamethasone suppresses inflammation and immune response, combining antimicrobial and anti-inflammatory effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Clindamycin+Dexamethasone TARGET	Clindamycin+Dexamethasone	Shahid Beheshti University of Medical Sciences	phase 3	Antibiotic + Corticosteroid combination	Bacterial 50S ribosome (clindamycin); Glucocorticoid receptor (dexamethasone)
Antibiotics + Corticosteroids	Antibiotics + Corticosteroids	George Washington University	marketed	Antibiotic + Corticosteroid combination
Tobramycin + Dexamethasone	Tobramycin + Dexamethasone	Umm Al-Qura University	marketed	Antibiotic + corticosteroid combination	Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)
moxifloxacin / dexamethasone	moxifloxacin / dexamethasone	Federal University of São Paulo	marketed	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor
Moxifloxacin / Dexamethasone Ophthalmic Solution	Moxifloxacin / Dexamethasone Ophthalmic Solution	Laboratorios Sophia S.A de C.V.	phase 3	Fluoroquinolone antibiotic + Corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)
Levofloxacin + dexamethasone followed by dexamethasone	Levofloxacin + dexamethasone followed by dexamethasone	NTC srl	phase 3	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone)
Ciprofloxacin HCl and Hydrocortisone	Ciprofloxacin HCl and Hydrocortisone	Farmoquimica S.A.	phase 3	Fluoroquinolone antibiotic + corticosteroid combination	Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic + Corticosteroid combination class)

George Washington University · 1 drug in this class
Shahid Beheshti University of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clindamycin+Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/clindamycin-dexamethasone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing